You have 9 free searches left this month | to do more
Showing 1 - 25 of
174 items
Trials Per Page
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
M
Completed
  • Human Immunodeficiency Virus (HIV)
  • Ixazomib 1 MG
  • +3 more
  • Rochester, Minnesota
    Mayo Clinic
2021-12-08
Dec 8, 2021
H
Recruiting
  • Mantle Cell Lymphoma
  • Ixazomib
  • Busan, Western, Korea, Republic of
    Kosin University Gospel Hospital
2022-03-31
Mar 31, 2022
D
Active, not recruiting
  • Smoldering Multiple Myeloma
  • Ixazomib
  • +2 more
  • Boston, Massachusetts
    Dana Farber Cancer Institute
2022-03-15
Mar 15, 2022
M
Active, not recruiting
  • Solid Tumors
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
2022-02-09
Feb 9, 2022
P
Recruiting
  • Multiple Myeloma
  • Multiple Myeloma in Relapse
  • Ixazomib
  • +2 more
  • Boston, Massachusetts
    Dana Farber Cancer Institute
2022-02-28
Feb 28, 2022
F
Active, not recruiting
  • Plasma Cell Myeloma
  • Transplant-Related Carcinoma
  • Ixazomib Citrate
  • +2 more
  • Seattle, Washington
    Fred Hutchinson Cancer Research Center
2022-04-04
Apr 4, 2022
Q
Recruiting
  • Relapsing Remitting Multiple Sclerosis
  • +2 more
  • Ixazomib (NINLARO®) capsules / Matching placebo capsules
  • London, Greater London, United Kingdom
    Royal London Hospital, Barts Health NHS Foundation Trust
2022-02-17
Feb 17, 2022
E
Completed
  • Glioblastoma
  • Ixazomib
  • Atlanta, Georgia
    Emory University/Winship Cancer Institute
2021-03-02
Mar 2, 2021
E
Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Atlanta, Georgia
  • +3 more
2022-01-05
Jan 5, 2022
U
Completed
  • Kidney Diseases
  • End Stage Renal Disease
  • Ixazomib Oral Capsule
  • Madison, Wisconsin
    University of Wisconsin Hospital and Clinics
2021-05-03
May 3, 2021
E
Active, not recruiting
  • Mantle Cell Lymphoma
  • Ixazomib
  • Rituximab
  • Atlanta, Georgia
  • +1 more
2021-10-26
Oct 26, 2021
J
Active, not recruiting
  • Myeloma
  • La Jolla, California
  • +2 more
2022-03-14
Mar 14, 2022
T
Completed
  • Relapsed and/or Refractory Multiple Myeloma
  • Ixazomib
  • +2 more
  • Tokyo, Japan
    Takeda Selected Site
2021-06-03
Jun 3, 2021
A
Recruiting
  • Kaposi Sarcoma
  • Skin
  • Ixazomib Citrate
  • +2 more
  • Los Angeles, California
  • +1 more
2021-03-26
Mar 26, 2021
M
Suspended
  • Recurrent Waldenstrom Macroglobulinemia
  • +2 more
  • Jacksonville, Florida
  • +1 more
2021-08-02
Aug 2, 2021
P
Active, not recruiting
  • Mantle-Cell Lymphoma
  • Atlanta, Georgia
  • +13 more
2022-03-31
Mar 31, 2022
H
Terminated
  • AML
  • AML, Adult
  • Indianapolis, Indiana
    Indiana University Melvin and Bren Simon Cancer Center
2022-03-15
Mar 15, 2022
M
Completed
  • Myeloid Hematologic Malignancy
  • Lymphoid Hematologic Malignancy
  • Ixazomib
  • New York, New York
    Memorial Sloan Kettering Cancer Center
2021-09-03
Sep 3, 2021
T
Recruiting
  • Multiple Myeloma
  • No Intervention
  • Hwasun-gun, Jeollanam-do, Korea, Republic of
    (unnamed)
2021-04-14
Apr 14, 2021
M
Recruiting
  • AL Amyloidosis
  • Boston, Massachusetts
  • +7 more
2022-01-21
Jan 21, 2022
M
Active, not recruiting
  • Multiple Myeloma
  • High Risk Smoldering Multiple Myeloma
  • Basking Ridge, New Jersey
  • +5 more
2021-11-15
Nov 15, 2021
M
Active, not recruiting
  • Hematopoietic Cell Transplantation Recipient
  • Plasma Cell Myeloma
  • Ixazomib Citrate
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-03-08
Mar 8, 2022
U
Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • +8 more
  • Ixazomib Citrate
  • +2 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2021-10-20
Oct 20, 2021
B
Active, not recruiting
  • B Cell Lymphoma
  • Lymphoma
  • Ixazomib
  • +2 more
  • Cleveland, Ohio
  • +1 more
2022-03-03
Mar 3, 2022